PROKIDNEY CORP. 8-K

What Happened
ProKidney Corp. (PROK) filed a Form 8‑K on May 15, 2026 to furnish a press release announcing its financial results for the quarter ended March 31, 2026 (Exhibit 99.1). The company also updated its investor presentation (Exhibit 99.2), available on its investor website. Management reports the Phase 3 PROACT 1 trial is on track to complete enrollment for the accelerated‑approval analysis in mid‑2026, with pivotal topline results expected in Q2 2027.

Key Details

• Filing date: May 15, 2026; quarter covered: ended March 31, 2026.
• PROACT 1 trial: expected enrollment completion mid‑2026; topline results anticipated Q2 2027.
• Statistical power: study has 90% power to detect an annualized eGFR slope effect of 1.75 mL/min/1.73m2 and 80% power to detect 1.5 mL/min/1.73m2. Company notes FDA (under RMAT designation) agreed 1.5 mL/min/1.73m2 could demonstrate efficacy for accelerated approval.
• Updated assumptions: the powering assumption for the surrogate (eGFR slope) analysis was updated to 80%; confirmatory endpoint powering remains 80%.
• Context: In Phase 2 REGEN‑007 (Group 1), rilparencel bilateral kidney injections were associated with a 4.6 mL/min/1.73m2 improvement in annual eGFR slope.
• Financial outlook: the company expects current cash to support operations into mid‑2027 (forward‑looking, subject to risks). Report signed by CFO James Coulston.

Why It Matters
The filing confirms progress on ProKidney’s lead Phase 3 study and provides concrete timing and statistical assumptions that matter for regulatory and commercial prospects. Completion of enrollment and a Q2 2027 topline readout are key milestones that could affect the company’s valuation and funding needs. The FDA’s acceptance that a 1.5 mL/min/1.73m2 eGFR slope effect could support accelerated approval (under RMAT) is material because it defines a potential regulatory path; however, outcomes remain subject to trial results and typical regulatory risk. The stated cash runway into mid‑2027 signals investors should watch financing needs and upcoming clinical readouts.